沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病的疗效观察

目的 观察沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病(COPD)的临床疗效.方法 108例COPD患者,随机分为实验组和对照组,各54例.对照组予口服盐酸氨溴索片、茶碱缓释片等进行常规治疗,实验组在常规治疗的基础上同时给予沙美特罗替卡松粉吸入治疗.比较两组患者治疗前后的肺功能指标[第1秒用力呼气容积(FEV1)、第1秒...

Observation on efficacy of salmeterol xinafoate and fluticasone propionate powder for inhalation for the treatment of chronic obstructive pulmonary disease

Objective To observe the clinical efficacy of salmeterol xinafoate and fluticasone propionate powder for inhalation for the treatment of chronic obstructive pulmonary disease(COPD). Methods A total of 108 COPD patients were randomly divided into experimental group and control group, with 54 cases in each group. The control group received oral administration of ambroxol hydrochloride tablets and theophylline sustained-release tablets for conventional treatment, and the experimental group received salmeterol xinafoate and fluticasone propionate powder for inhalation on the basis of conventional treatment. The pulmonary function indexes [forced expiratory volume in the 1 st second(FEV1) and FEV1/forced vital capacity(FEV1/FVC)], arterial blood gas analysis indexes [arterial oxygen partial pressure(PaO2) and arterial carbon dioxide partial pressure(PaCO2)] and COPD assessment test(CAT) score before and after treatment and occurrence of adverse reactions were compared between the two groups. Results In the control group, FEV1, FEV1/FVC, PaO2, PaCO2, and CAT score after treatment were(1.68±0.13) L,(52.44±6.81)%,(64.40±7.89)mm Hg(1 mm Hg=0.133 kPa),(51.60±6.50) mm Hg and(32.6±6.5) points, which had no statistically significant difference compared with those before treatment(1.61±0.13) L,(51.10±6.08)%,(62.00±7.15) mm Hg,(52.20±6.42) mm Hg and(33.1±6.7) points(P>0.05). In the experimental group, FEV1, FEV1/FVC, PaO2 after treatment were(1.94±0.11) L,(63.48±6.52)%,(74.80±8.21) mm Hg, which were higher than those before treatment(1.58±0.16) L,(50.90±5.96)%,(61.60±7.08) mm Hg, and PaCO2, CAT score(40.80±6.35) mm Hg,(21.8±5.8) points were lower than those before treatment(52.50±6.36) mm Hg,(32.4±6.5) points. The difference was statistically significant(P<0.05). After treatment, FEV1, FEV1/FVC, PaO2 of the experimental group were higher than those of the control group, and PaCO2, CAT score were lower than those of the control group. The difference was statistically significant(P<0.05). There were no significant adverse reactions in both groups. Conclusion Salmeterol xinafoate and fluticasone propionate powder for inhalation can significantly improve the clinical symptoms and pulmonary function of COPD patients.